Early Breast Cancer: Do We Need Chemotherapy In Low Genomic/High Clinical Risk

Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?

Do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)

Oncology Frontier

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

Adjuvant Treatment for Early Stage Hormone Positive Breast Cancer: Role of Genomic Signatures

Total Health | Oncology

Should chemotherapy be used in post-menopausal patients with low genomic risk HR+ breast cancer?

New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identification

Touch Medical Media

Adjuvant/Neoadjuvant Therapy for Breast Cancer: Updates and Molecular Predictors of Benefit

Will genomic profiling replace clinical and pathological risk factors in ER+ breast cancer?

Can we decrease chemotherapy in LN+ premenopausal women based on genomic tests?

Updated findings on low-risk MINDACT participants reported | Laura van 't Veer

Medicine Matters oncology

Risk of Early Versus Late Recurrence

Results of the MINDACT clinical trial

Using MammaPrint to select patients who may not need adjuvant chemotherapy – the results of MINDACT

Defining Optimal Therapy in High-Risk Early Breast Cancer #shorts

Treatment options for high risk early breast cancer

Genomic Profiling in early stage breast cancer & Role of Mammaprint & Blueprint testing | Oncquest

Oncquest Laboratories Ltd.

Molecular profiling in early breast cancer

Reshma Mahtani, DO | Sylvester Cancer | ASCO20 Breast Cancer Reactions: MINDACT for Early Stage

Total Health | Oncology

Dr. Aju Mathew, Assistant Professor of Medicine talking on Breast Cancer at our Foster City Lab

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in br...